Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies
- PMID: 20090669
- PMCID: PMC3055399
- DOI: 10.1038/npp.2009.211
Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies
Abstract
In this article, we review the literature on practice effects in schizophrenia, an underappreciated confound in interpreting cognitive improvement in clinical trials. We first examine claims regarding first- and second-generation antipsychotic medications as cognitive enhancers, and follow it with a discussion of recent studies demonstrating how practice or placebo effects may drive 'positive' findings. Thus, this review suggests that many previous findings can be reinterpreted in this light. Critically, we also make several suggestions about test construction, study design, and statistical analyses that the field might use to overcome this potential confound. Our suggestions may also have implications for drug discovery and regulatory approval of cognitive-enhancing adjunctive agents, in terms of study design and/or test psychometric characteristics, including the development of tests that are relatively insensitive to practice-related changes. Such advances might be important for improving the methodology involved in the assessment of cognitive change in treatment studies.
Similar articles
-
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?Arch Gen Psychiatry. 2007 Oct;64(10):1115-22. doi: 10.1001/archpsyc.64.10.1115. Arch Gen Psychiatry. 2007. PMID: 17909123 Clinical Trial.
-
Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.Am J Psychiatry. 2001 Feb;158(2):176-84. doi: 10.1176/appi.ajp.158.2.176. Am J Psychiatry. 2001. PMID: 11156796 Review.
-
Important steps in the development of cognitive-enhancing drugs in schizophrenia.Am J Psychiatry. 2006 Nov;163(11):1867-9. doi: 10.1176/ajp.2006.163.11.1867. Am J Psychiatry. 2006. PMID: 17074932 No abstract available.
-
Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.Arch Gen Psychiatry. 2007 Jun;64(6):631-2. doi: 10.1001/archpsyc.64.6.631. Arch Gen Psychiatry. 2007. PMID: 17548745 No abstract available.
-
Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.Schizophr Bull. 2007 Sep;33(5):1131-7. doi: 10.1093/schbul/sbm081. Epub 2007 Jul 14. Schizophr Bull. 2007. PMID: 17630405 Free PMC article. Review.
Cited by
-
Lower practice effects as a marker of cognitive performance and dementia risk: A literature review.Alzheimers Dement (Amst). 2020 Jul 9;12(1):e12055. doi: 10.1002/dad2.12055. eCollection 2020. Alzheimers Dement (Amst). 2020. PMID: 32671181 Free PMC article.
-
Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials.Alzheimers Dement (Amst). 2015 Mar 29;1(1):103-11. doi: 10.1016/j.dadm.2014.11.003. eCollection 2015 Mar. Alzheimers Dement (Amst). 2015. PMID: 27239497 Free PMC article.
-
Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer's Disease Spectrum.Innov Clin Neurosci. 2017 Feb 1;14(1-2):30-39. eCollection 2017 Jan-Feb. Innov Clin Neurosci. 2017. PMID: 28386519 Free PMC article. Review.
-
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.J Am Acad Child Adolesc Psychiatry. 2012 May;51(5):496-505. doi: 10.1016/j.jaac.2012.02.001. Epub 2012 Mar 13. J Am Acad Child Adolesc Psychiatry. 2012. PMID: 22525956 Free PMC article. Clinical Trial.
-
Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients.Psychol Med. 2013 Jun;43(6):1161-73. doi: 10.1017/S0033291712002127. Epub 2012 Dec 14. Psychol Med. 2013. PMID: 23237010 Free PMC article. Clinical Trial.
References
-
- Ahn YM, Lee KY, Kim CE, Kim JJ, Kang DY, Jun TY, et al. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. J Clin Psychopharmacol. 2009;29:117–123. - PubMed
-
- Albus M, Hubmann W, Mohr F, Hecht S, Hinterberger-Weber P, Seitz NN, et al. Neurocognitive functioning in patients with first-episode schizophrenia. Eur Arch Psychiatry Clin Neurol. 2006;256:442–451. - PubMed
-
- Basso MR, Bornstein RA, Lang JM. Practice effects on commonly used measures of executive function across twelve months. Clin Neuropsychol. 1999;13:283–292. - PubMed
-
- Beglinger LJ, Gaydos B, Tangphao-Daniels O, Duff K, Kareken DA, Crawford J, et al. Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol. 2005;20:517–529. - PubMed
-
- Boulay LJ, Labelle A, Bourget D, Robertson S, Habib R, Tessier P, et al. Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: olanzapine versus haloperidol. Cogn Neuropsychiatry. 2007;12:322–338. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical